Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker
Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker
复制标题
DOI：
10.1007/s10147-013-0565-2
复制
发表时间：
2014-04-01
影响因子：
3.3
通讯作者：
Hirahara, Fumiki
中科院分区：
文献类型：
--
作者：
Ihata, Yutaka;Miyagi, Etsuko;Hirahara, Fumiki
不同癌症患者的血浆氨基酸谱(PAAP)有所不同，有人认为它们可能有助于几种癌症的早期检测。我们评价了一种由多种血浆氨基酸组成的新的生物标志物对子宫内膜癌的诊断性能，并与CA125的诊断性能进行了比较。对80例子宫内膜癌患者、122例妇科良性疾病患者和240例年龄和体重指数匹配的对照组进行了血浆氨基酸水平的测定。在单因素分析后，我们应用基于PAAP多变量分析的多元模型来区分子宫内膜癌患者和对照组。比较多项PAAP指数(API)和CA125对子宫内膜癌的诊断价值。用于区分子宫内膜癌患者和对照组的受试者工作特征曲线(AUC)下面积为0.94。API的AUC值显著大于CA125(P=0.0068)。对于98.3%的特异度，API的敏感性(60.0%，95%CI，43.3~75.1)显著高于CA125(22.5%，95%CI，10.1~38.5)。在I期子宫内膜癌中，API的阳性率显著高于CA125(P=0.0002)，其早期诊断子宫内膜癌的敏感性和疾病特异度均优于CA125。这一新的血浆生物标志物有可能成为子宫内膜癌的诊断和筛查标志物。
Plasma amino acid profiles (PAAPs) vary in individual cancer patients, and it has been suggested that they may be useful for early detection of several types of cancer. We evaluated the diagnostic performance of a profile index for endometrial cancer composed of multiple plasma amino acids as a novel biomarker and compared its diagnostic performance with that of CA125.Plasma amino acid levels of 80 patients with endometrial cancer, 122 with benign gynecological diseases, and 240 age- and body mass index-matched control subjects were measured using liquid chromatography and mass spectrometry. After univariate analysis, we applied a multiplex model based on the PAAP multivariate analysis to distinguish patients with endometrial cancer from control subjects. We compared the diagnostic performance of the multiple PAAP index (API) with that of CA125.The levels of several plasma amino acids were significantly different in patients with endometrial cancer. The area under the receiver operating characteristic curves (AUC) used to distinguish endometrial cancer patients from control subjects was 0.94. The AUC for API was significantly larger than that for CA125 (P = 0.0068). For the same specificity of 98.3 %, API showed a significantly higher sensitivity (60.0 %, 95 % CI, 43.3-75.1) than that of CA125 (22.5 %, 95 % CI, 10.1-38.5). In stage I cases, API showed significantly higher positivity than that of CA125 (P = 0.0002).The sensitivity and disease specificity of API for early-stage detection of endometrial cancer was superior to CA125. This novel plasma biomarker has the potential to become a diagnostic and screening marker for endometrial cancer.